Cargando...
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent yea...
Gardado en:
| Publicado en: | Theranostics |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Ivyspring International Publisher
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299695/ https://ncbi.nlm.nih.gov/pubmed/30613284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.30357 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|